Participated · Series B · Jul 2024

Foresight Diagnostics develops the Foresight CLARITY™ liquid biopsy MRD testing platform, an ultrasensitive assay based on PhasED‑Seq that reports detection limits in parts per million. The platform lowers sequencing error by requiring concordant detection of multiple non‑reference events in a single DNA molecule to distinguish tumor ctDNA from healthy cfDNA. Foresight operates a CLIA‑registered laboratory and has invested in automation and a new laboratory in Boulder to scale operations. The company is advancing evidence generation in lymphoma and solid tumors and has initiated the prospective Phase 2 ALPHA3 trial in partnership with Allogene Therapeutics using its CLARITY IUO test. PhasED‑Seq recently received an IDE approval from the U.S. FDA for investigational use in that study. To date, Foresight has raised $86 million in venture financing. Foresight Diagnostics develops a liquid biopsy testing platform, PhasED-Seq, for measurement of minimal residual disease to inform treatment decisions for solid tumors and hematologic malignancies. The company operates a CLIA-registered laboratory and positions its tests to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches. Led by CEO Jake Chabon, Foresight intends to use the new funding to accelerate clinical development and commercialization of its cancer recurrence testing platform, PhasED-Seq. The company raised $58.75M in a Series B financing to support those efforts. Uplaksh Kumar, Ph.D., will join the company's board of directors as part of the financing. The company is based in Aurora, CO.

Participated · Series A · Feb 2023

CodaMetrix offers an AI-driven platform for multi-specialty medical coding with real-time audit capabilities, seamless EHR integration, and a patient-centric longitudinal view of records. Built in partnership with provider organizations, the platform is designed to continuously improve AI learning through feedback loops. It is deployed at more than a dozen provider organizations representing over 200 hospitals and 50,000 providers. Providers using CodaMetrix report a 60% reduction in coding costs, a 70% reduction in claims denials, and a five-week acceleration in time to cash, along with improved provider satisfaction, quality, and compliance. The company targets a roughly $20B annual market for multi-specialty coding and is recognized by KLAS Research as No. 1 in the “Reduce Cost of Care” category. CodaMetrix plans to use new funding to further advance its AI-powered solutions to improve coding quality, produce clinically comprehensive datasets, reduce overall cost of care, and alleviate administrative burden on providers. CodaMetrix provides an AI-powered SaaS platform to support healthcare revenue cycle management and medical coding. Its platform combines machine learning, deep learning, and natural language processing to translate clinical notes automatically and accurately into billing and diagnostic codes, reducing human coding workload. The AI continuously learns from clinical evidence in electronic health records to improve coding efficiency and quality. CodaMetrix is currently partnered with 10 health systems and major academic institutions, including Mass General Brigham, University of Colorado Medicine, Yale Medicine, and Henry Ford Health Systems. It closed a $55M Series A in February 2023 and plans to use the funds to accelerate go-to-market with major provider organizations and health systems. The company is led by President and CEO Hamid Tabatabaie.

Participated · Equity · Mar 2021

Riva Health builds a mobile cardiology application that measures and manages hypertension by capturing a high-resolution blood-pulse waveform (BPW) via fingertip photoplethysmography (PPG) using a phone camera. The company couples this novel measurement technology with interventions delivered by its licensed healthcare providers to enable higher-fidelity remote patient management and broader access to premium heart care. Led by CEO Dag Kittlaus and co-founder Tuhin Sinha, PhD, Riva is completing comprehensive validation of its measurement technology with world experts and is working with the FDA for marketing clearance. The company plans to launch the beta of its flagship app in summer 2021 and is hiring for its engineering team. Riva intends to use recently raised funds to expand operations.

Participated · Series B · Nov 2020

Q32 Bio is a clinical-stage biotechnology company based in Cambridge, Mass., developing biologic therapeutics to restore healthy immune regulation by targeting regulators of the innate and adaptive immune systems. Its lead programs target the IL-7R pathway (ADX-914) and the complement system (ADX-097). ADX-914 is a fully human anti-IL-7R antibody in a first-in-human trial designed to evaluate safety, tolerability and demonstrate proof-of-mechanism. ADX-097 is a fusion protein from Q32’s tissue-targeted complement regulation platform and was expected to enter Phase 1 in Q4 2021. The company is led by CEO Michael Broxson and intends to use new funds to advance ADX-914 through proof-of-mechanism, further develop its complement platform, and expand its platform and pipeline. Q32 Bio is a Cambridge, Massachusetts-based biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. The company focuses on biologics designed to restore healthy immune regulation, including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R). It also operates a complement therapeutics platform that has generated fusion proteins to downregulate complement activity specifically in disease-affected tissues. Q32 Bio's most advanced program, ADX-914, is a fully human anti-IL-7R antibody licensed from Bristol Myers Squibb that aims to re-regulate adaptive immune function. The company was seeded and incubated by Atlas Venture and builds on foundational science from researchers at the University of Colorado and the Medical University of South Carolina. Q32 Bio is led by CEO and co-founder Michael Broxson and CSO and President of Research Shelia Violette, Ph.D.

Participated · Series A · Oct 2019

IM Therapeutics is a clinical-stage company building personalized oral therapies that block disease‑associated HLA variants to treat autoimmune diseases. Its platform combines computational chemistry, bioassays and rational drug design to screen millions of compounds for optimal docking within HLA proteins. The company's lead candidate, oral IMT-002, is directed at HLA DQ8 and is being advanced through IND development for type 1 diabetes after a Phase 1b study showed inhibition of the autoimmune response in recently diagnosed, DQ8-positive patients. IM Therapeutics was founded by physician-scientists at the Barbara Davis Center for Diabetes (University of Colorado) and is expanding its HLA blockade platform to additional targets including celiac disease. Management includes CEO Nandan Padukone, and the company recently added investor representatives to its board. Financially, the company announced a $10 million Series A to advance its discovery platform and clinical program.